Bispecifics
Bispecifics
Accelerate Bispecific Antibody Programs Through Smarter Formulation Design
Accelerate Bispecific Antibody Programs Through Smarter Formulation Design
Bispecific antibodies offer great promise—
but their complex structures create
unique formulation and stability hurdles.
Bispecific antibodies offer great promise—
but their complex structures create
unique formulation and stability hurdles.
Bispecific antibodies offer great promise—
but their complex structures create
unique formulation and stability hurdles.
In this white paper, you'll learn to:
Partner with Leukocare for tailored, data‑driven solutions that bring your biologics closer to patients.
Let’s Build the Right Formulation — Together
Anticipate and avoid pitfalls that commonly derail bispecific formulations
Anticipate and avoid pitfalls that commonly derail bispecific formulations
Role of molecular modeling and machine learning to predict excipients
Leverage data-driven strategies to reduce risk and speed development
Manufacturability & administrability - We analyze adsorption, pH-jump effects, high-concentration viscosity and container-closure interactions to ensure that what looks feasible in silico also works in practice. This step bridges stability with usability.
Related service: Primary Packaging Assessment
See how theory translates into practice through a real-world case example
Manufacturability & administrability - We analyze adsorption, pH-jump effects, high-concentration viscosity and container-closure interactions to ensure that what looks feasible in silico also works in practice. This step bridges stability with usability.
Related service: Primary Packaging Assessment
Embedded HubSpot Form
Designed for biotech scientists, formulation leaders, and CMC professionals, this interactive session will show you why bsAbs are challenging to formulate, how predictive tools reduce risk, and how systematic excipient selection saves time and material—plus what to expect from a true strategic formulation partner.
See these strategies in action. Join the webinar:
See these strategies in action. Join the webinar:
Designed for biotech scientists, formulation leaders, and CMC professionals, this interactive session will show you why bsAbs are challenging to formulate, how predictive tools reduce risk, and how systematic excipient selection saves time and material—plus what to expect from a true strategic formulation partner.
Contact
Ready to talk about your bispecific formulation strategy?
Our experts work with leading biotech companies to solve complex formulation challenges. If you’d like to discuss your molecule and explore tailored solutions, we’d be happy to connect.
Reach out now
Ulrike Konrad - VP Business Development
Ready to talk about your bispecific formulation strategy?
Turning complex molecules into robust drug products
Ready to Talk About Your Bispecific Program?
Turning complex molecules into robust drug products
Designed for biotech scientists, formulation leaders, and CMC professionals, this interactive session will show you why bsAbs are challenging to formulate, how predictive tools reduce risk, and how systematic excipient selection saves time and material—plus what to expect from a true strategic formulation partner.